#製藥

Dr Reddy's Semaglutide Supply Disruption Triggers 9% Stock Drop, Brokerage Downgrades

Dr Reddy's Laboratories shares crashed 9% over two days following a supply disruption of its semaglutide product due to API quality issues, highlighting execution risks in the high-demand GLP-1 drug market.

Williams·Jul 10, 2026·2 min read